NCT05108519

Brief Summary

This study collects information about complications and clinical response in cancer patients treated with anti-VEGF-related therapies. This study aims to observe side effects that may happen to patients with advanced cancer who are treated with anti-VEGF related therapy. This may help doctors learn if there are any relationships between these side effects and how the disease may respond to treatment.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
170

participants targeted

Target at P50-P75 for all trials

Timeline
7mo left

Started Apr 2019

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress92%
Apr 2019Feb 2027

Study Start

First participant enrolled

April 8, 2019

Completed
2.6 years until next milestone

First Submitted

Initial submission to the registry

October 25, 2021

Completed
11 days until next milestone

First Posted

Study publicly available on registry

November 5, 2021

Completed
5.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 2, 2027

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 2, 2027

Last Updated

February 19, 2026

Status Verified

February 1, 2026

Enrollment Period

7.8 years

First QC Date

October 25, 2021

Last Update Submit

February 17, 2026

Conditions

Hematopoietic and Lymphoid Cell NeoplasmMalignant Solid Neoplasm

Outcome Measures

Primary Outcomes (1)

  • Incidence of grade 3+ adverse events (AE) at least possibly related to anti-VEGF-related treatment (overall and each type separately)

    For each toxicity, will estimate the odds ratio, associated 95% confidence interval and p-value.

    Up to 5 years

Study Arms (1)

Observational (medical records review)

Patients' medical records are reviewed.

Other: Electronic Health Record Review

Interventions

Electronic Health Record ReviewOTHER

Medical records are reviewed

Observational (medical records review)

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients receiving any anti-VEGF-related regimen

You may qualify if:

  • Patients must be able to understand and be willing to sign a written informed consent document
  • Patients must be receiving any anti-VEGF-related regimen in monotherapy or combination therapy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

M D Anderson Cancer Center

Houston, Texas, 77030, United States

RECRUITING

Related Links

MeSH Terms

Conditions

Hematologic Neoplasms

Condition Hierarchy (Ancestors)

Neoplasms by SiteNeoplasmsHematologic DiseasesHemic and Lymphatic Diseases

Study Officials

  • Nicolas L Palaskas

    M.D. Anderson Cancer Center

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
OTHER
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 25, 2021

First Posted

November 5, 2021

Study Start

April 8, 2019

Primary Completion (Estimated)

February 2, 2027

Study Completion (Estimated)

February 2, 2027

Last Updated

February 19, 2026

Record last verified: 2026-02

Locations

US(1)